Pharmacotherapy For Cardiovascular Disorders

As an advanced practice nurse, it is your responsibility to recommend appropriate treatment options for patients with cardiovascular disorders. To ensure the safety and effectiveness of drug therapy, advanced practice nurses must consider aspects that might influence pharmacokinetic and pharmacodynamic processes such as medical history, other drugs currently prescribed, and individual patient factors.

Reference: Murphy, S. L., Xu, J., Kochanek, K. D., & Arias, E. (2018). Mortality in the United States, 2017. Retrieved from https://www.cdc.gov/nchs/products/databriefs/db328.htm

To Prepare

• Review the Resources for this module and consider the impact of potential pharmacotherapeutics for cardiovascular disorders introduced in the media piece.
• Review the case study assigned by your Instructor for this Assignment.
• Select one the following factors: genetics, gender, ethnicity, age, or behavior factors.
• Reflect on how the factor you selected might influence the patient’s pharmacokinetic and pharmacodynamic processes.
• Consider how changes in the pharmacokinetic and pharmacodynamic processes might impact the patient’s recommended drug therapy.
• Think about how you might improve the patient’s drug therapy plan based on the pharmacokinetic and pharmacodynamic changes. Reflect on whether you would modify the current drug treatment or provide an alternative treatment option for the patient.

you will examine how patient factors may influence pharmacokinetic and pharmacodynamic processes of pharmacotherapeutics used in the treatment of cardiovascular disorders.  You also explore ways to improve drug therapy plans for cardiovascular disorders based on patient factors and overall health needs.

When writing your Week 2 Assignment, consider the following scenario:

Patient CB has a history of strokes. The patient has been diagnosed with type 2 diabetes, hypertension, and hyperlipidemia. Drugs currently prescribed include the following:

•     Glipizide 10 mg op daily

•     HCTZ 25 mg daily

•     Atenolol 25 mg po daily

•     Hydralazine 25 mg QID

•     Simvastatin 80 mg daily   

•     Verapamil 180 mg CD daily

Evidence-based clinical practice guidelines are fundamental to clinical practice, as they assist providers with clinical decision making.  I have attached some applicable guidelines below for your reference.

2017 ACC-AHA Guideline Mgmt HTN in Adults.pdf

2018 AHA-ACC Guideline on Mgmt Blood Cholesterol.pdf

2017 ACC-AHA-HFSA Guideline Mgmt HF.pdf

ASH 2018 Guidelines Mgmt of VTE_Optimal Anticoag.pdf

2019 AHA-ACC-HRS Guideline for Mgmt A Fib.pdf

2017 AHA-ACC Guideline Mgmt Valvular Heart Disease.pdf

Write a 2- to 3-page paper that addresses the following:

• Explain how the factor you selected might influence the pharmacokinetic and pharmacodynamic processes in the patient from the case study you were assigned.
• Describe how changes in the processes might impact the patient’s recommended drug therapy. Be specific and provide examples.
• Explain how you might improve the patient’s drug therapy plan and explain why you would make these recommended improvements.